Published on
Last updated on
Webinar: MedTech pathway to China: Market opportunities and regulatory hurdles
Date: June 24, 2020
Time: 03:00 PM in Hong Kong SAR
Are you a MedTech manufacturer looking to expand sales? Interested in the Chinese market, but not sure where to start? Concerned about information, distribution and regulatory hurdles? Have current business in China, but not satisfied with your distributor or market approach?
China’s insatiable healthcare demand has been only further accelerated by the Covid-19 emergency. In this exclusive webinar, market-leading consulting firm Fiducia and one of China’s longest standing regulatory affairs specialists Cisema jointly analyse and describe the market opportunities and regulatory hurdles for MedTech in China.
Cisema will provide an overview on how to register your MedTech product for sale in China with the NMPA (former CFDA) and provide insight into China’s fast-changing regulatory landscape with its increasing focus on post-market surveillance. You will learn how to establish a lean and efficient distribution set-up as Fiducia reveals and analyses its brand-new medical market insights together with their latest project case studies.
Related News
Malaysia Introduces New e-IFU & Digital Labelling Guidance for Medical Devices
Malaysia’s MDA publishes the 7th edition of guidance on medical device labelling, with new e-labelling, e-IFU, and accessibility requirements
Vietnam Authorities Step Up Cosmetic Recalls as Enforcement Tightens
Vietnam’s Drug Administration (DAV) is stepping up cosmetic product recalls as post-market surveillance tightens.
BPOM Clarifies Indonesia–US Trade Agreement Impact on Pharmaceutical Regulation
BPOM confirms pharmaceutical authorization, GMP oversight, and regulatory authority remain unchanged under the Indonesia–US trade agreement.